Amundi Boosts Position in Illumina, Inc. $ILMN

Amundi boosted its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 14.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 351,999 shares of the life sciences company's stock after purchasing an additional 44,337 shares during the period. Amundi owned approximately 0.23% of Illumina worth $43,387,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in ILMN. Empowered Funds LLC raised its holdings in Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company's stock valued at $737,000 after acquiring an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of Illumina during the second quarter worth about $621,000. CW Advisors LLC bought a new position in shares of Illumina during the second quarter worth about $275,000. Marshall Wace LLP grew its stake in Illumina by 49.0% in the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company's stock worth $5,691,000 after purchasing an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC increased its holdings in Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company's stock valued at $706,000 after buying an additional 1,748 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q2 results exceeded expectations: Illumina reported $1.16 billion in revenue, up approximately 9.4%–9.5% year over year, while non-GAAP diluted EPS of $1.31 topped the $1.23 consensus estimate. Clinical demand and NovaSeq X placements were key growth drivers. Illumina Q2 financial results
• Positive Sentiment: Full-year guidance was raised: Management increased fiscal 2026 non-GAAP EPS guidance to $5.30–$5.40 and revenue guidance to approximately $4.60–$4.64 billion, modestly ahead of analyst expectations. Illumina outlook
• Positive Sentiment: Analysts raised price targets: JPMorgan lifted its target to $230 and maintained an “overweight” rating; Stifel raised its target to $225 and assigned a “buy” rating. TD Cowen increased its target to $210 but retained a “hold” rating. These revisions signal greater confidence in Illumina’s earnings outlook, although targets vary considerably.
• Positive Sentiment: AI and drug-discovery opportunities remain a catalyst: CEO Jacob Thaysen highlighted genomic medicine and artificial intelligence applications in life sciences. Eli Lilly also joined Illumina’s Billion Cell Atlas alliance, which aims to create large-scale genomic datasets for identifying disease mechanisms and drug targets. Eli Lilly joins Billion Cell Atlas
• Neutral Sentiment: Investors are taking profits near record levels: With ILMN trading close to its one-year high, the strong results may have prompted a “sell-the-news” response as investors sought evidence of further upside beyond the guidance increase.
• Negative Sentiment: China and margins remain concerns: Greater China revenue declined 12%, while full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%. Management also expects NovaSeq X instrument-placement growth to moderate year over year in the second half. Illumina China and margin analysis
• Negative Sentiment: Insider selling may add pressure: Reported insider activity over the past six months included 41 sales and one purchase, though such transactions may reflect scheduled or personal portfolio activity rather than a direct view of fundamentals.

Insider Activity at Illumina

In other Illumina news, CAO Scott D. Ericksen sold 500 shares of the company's stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the sale, the chief accounting officer directly owned 14,446 shares of the company's stock, valued at approximately $2,311,360. This represents a 3.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total transaction of $110,700.00. Following the completion of the transaction, the insider owned 20,953 shares in the company, valued at approximately $3,771,540. This trade represents a 2.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock valued at $155,710,908 over the last quarter. Corporate insiders own 2.90% of the company's stock.

Illumina Price Performance

Shares of ILMN opened at $205.10 on Monday. The firm has a market capitalization of $31.03 billion, a price-to-earnings ratio of 38.26, a price-to-earnings-growth ratio of 2.94 and a beta of 1.47. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a one year low of $88.00 and a one year high of $205.93. The stock's fifty day moving average is $176.70 and its 200-day moving average is $147.25.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts anticipate that Illumina, Inc. will post 5.37 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on ILMN shares. Barclays increased their target price on Illumina from $145.00 to $160.00 and gave the stock an "underweight" rating in a report on Friday. Citigroup boosted their price target on Illumina from $80.00 to $95.00 and gave the company a "sell" rating in a report on Monday, May 4th. Wall Street Zen raised Illumina from a "hold" rating to a "buy" rating in a research report on Saturday. Evercore restated an "outperform" rating on shares of Illumina in a research note on Monday, July 6th. Finally, Daiwa Securities Group raised shares of Illumina from a "neutral" rating to an "outperform" rating and set a $155.00 price objective for the company in a report on Thursday, May 14th. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $175.47.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.